John C. Lee

John C. Lee, L. Yeh, Karen P. Betchel, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A fluorescence study of type I and type II receptors of bone morphogenetic proteins with bis-ANS (4, 4'-dianilino-1, 1'-bisnaphthyl-5, 5' disulfonic acid).

John C. Lee, M. Panda, L. Yeh, 2007, Biochimica et biophysica acta.

Characterization of ligand-binding properties of the human BMP type II receptor extracellular domain.

John C. Lee, A. Hinck, L. Yeh, 2008, Journal of molecular biology.

A host-guest relationship in bone morphogenetic protein receptor-II defines specificity in ligand-receptor recognition.

John C. Lee, J. Lee, W. Falcón, 2012, Biochemistry.

Long-Range Communication Network in the Type 1B Bone Morphogenetic Protein Receptor.

John C. Lee, J. Lee, W. Evangelista, 2015, Biochemistry.

Activation of the HIV-1 Long Terminal Repeat by Cytokines and Environmental Stress Requires an Active CSBP/p38 MAP Kinase*

John C. Lee, C. Debouck, P. Young, 1996, The Journal of Biological Chemistry.

Human Mitogen-activated Protein Kinase CSBP1, but Not CSBP2, Complements a hog1 Deletion in Yeast (*)

John C. Lee, M. Mclaughlin, G. P. Livi, 1995, The Journal of Biological Chemistry.

ERK Pathway Mediates the Activation of Cdk2 in IGF‐1–Induced Proliferation of Human Osteosarcoma MG‐63 Cells

John C. Lee, S. Kumar, M. Gowen, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS

John C. Lee, J. Adams, 2007 .

Inhibition of human monocyte IL-1 production by SK&F 86002

John C. Lee, P. Bender, N. Hanna, 1990 .

Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury.

John C. Lee, J. Adams, S. Nerurkar, 2002, The Journal of pharmacology and experimental therapeutics.

The Accessibility of Yeast Ribosomal Protein L1 as Probed by Proteolysis and Site-directed Mutagenesis Is Different in Intact 60 and 80 S Ribosome (*)

John C. Lee, J. Lee, C. Turgeon, 1996, The Journal of Biological Chemistry.

Guinea-Pig Sympathetic Neurons Channels During the Prolonged AHP in + K Activation of 2+ Diversity of Channels Involved in Ca

Benjamin J. Whalley, John C. Lee, J. Callaway, 2015 .

High murine blood persistence of phage T3 and suggested strategy for phage therapy

John C. Lee, P. Serwer, E. Wright, 2019, BMC Research Notes.

Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin

John C. Lee, J. Tuszynski, A. Weis, 2016, Investigational New Drugs.

The p38/RK mitogen‐activated protein kinase pathway regulates interleukin‐6 synthesis response to tumor necrosis factor.

W. Fiers, P. Cohen, John C. Lee, 1996, The EMBO journal.

c-fos and HSP70 gene expression in rat brains in high gravitation-induced cerebral ischemia

John C. Lee, A. Shahed, P. Werchan, 1995, Neuroscience Letters.

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1

Philip R. Cohen, P. Cohen, John C. Lee, 1995, FEBS letters.

Inhibition of p38 mitogen‐activated protein kinase provides neuroprotection in cerebral focal ischemia

S. Kassis, John C. Lee, A. A. Parsons, 2001, Medicinal research reviews.

Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase.

J. Boehm, S. Kassis, John C. Lee, 1997, Bioorganic & medicinal chemistry.

Inhibition of p38 MAP kinase as a therapeutic strategy.

D E Griswold, John C. Lee, J. Adams, 2000, Immunopharmacology.

Effects of osteogenic protein‐1 (OP‐1, BMP‐7) on gene expression in cultured medial collateral ligament cells

John C. Lee, L. Yeh, A. Tsai, 2003, Journal of cellular biochemistry.

Rapamycin inhibits BMP‐7‐induced osteogenic and lipogenic marker expressions in fetal rat calvarial cells

John C. Lee, M. Adamo, L. Yeh, 2013, Journal of cellular biochemistry.

Co-transfection with the osteogenic protein (OP)-1 gene and the insulin-like growth factor (IGF)-I gene enhanced osteoblastic cell differentiation.

John C. Lee, L. Yeh, 2006, Biochimica et biophysica acta.

Effects of cartilage-derived morphogenetic protein-3 on the expression of chondrogenic and osteoblastic markers in the pluripotent mesenchymal C3H10T1/2 cell line

John C. Lee, L. Yeh, 2010, Growth factors.

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

J. Boehm, John C. Lee, J. Adams, 2000, Arthritis and rheumatism.

Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite.

Qingbo Xu, M. Gorospe, John C. Lee, 1996, Free radical biology & medicine.

Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles.

J C Lee, John C. Lee, P. Young, 1997, Biochemical and biophysical research communications.

p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.

John C. Lee, J. Adams, J. Adams, 2001, Progress in medicinal chemistry.

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

John C. Lee, J. Adams, J. Adams, 2000, American journal of physiology. Lung cellular and molecular physiology.

Role of p38 mitogen-activated protein kinase (p38 MAPK) in cytokine-induced rat islet cell apoptosis.

John C. Lee, J. Lee, N. Welsh, 2001, Biochemical pharmacology.

SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

S. Kassis, John C. Lee, J. Adams, 2001, The Journal of pharmacology and experimental therapeutics.

Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.

D E Griswold, John C. Lee, J. Adams, 1996, The Journal of pharmacology and experimental therapeutics.

Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels.

John C. Lee, D. Taylor, J. Lee, 1997, Journal of immunology.

p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.

S. Kassis, John C. Lee, J. Adams, 1999, Pharmacology & therapeutics.

Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.

E. F. Smith, John C. Lee, J. Lee, 1994, International journal of immunopharmacology.

Identification of Mitogen-activated Protein ( MAP ) Kinase-activated Protein Kinase-3 , a Novel Substrate of CSBP p 38 MAP Kinase *

John C. Lee, G. P. Livi, P. Young, 1996 .

Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.

John C. Lee, J. Adams, J. Adams, 1999, Biochemical and biophysical research communications.

p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level.

John C. Lee, M. Gaestel, J. Lee, 1997, Biochemical and biophysical research communications.

Osteogenic protein-1-mediated insulin-like growth factor gene expression in primary cultures of rat osteoblastic cells.

John C. Lee, J. Lee, M. Adamo, 1996, Endocrinology.

John C. Lee, N. Bhat, Peisheng Zhang, 1998, The Journal of Neuroscience.